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Recent advances in the development of reduced-intensity conditioning (RIC) have allowed a broader range of
patients to access allogeneic hematopoietic stem cell transplantation (HSCT). Reconstitution of an effective
immune system post-transplant, including natural killer (NK) cells, is critical for both tumor control and
infectious disease control or prevention. The development and functions of NK cells in such settings remain
elusive. Here we analyzed NK cell development in HLA-matched HSCT from related or unrelated donors, after
RIC that included antithymocyte globulin (N ¼ 45 patients). Our data reveal that NK cells quickly recover after
RIC-HSCT, irrespective of donor type. Rapidly re-emerging NK cells, however, remain immature for more than
6 months. Effector functions resemble that of immature NK cells because they poorly produce IFN-g and
TNF-a in response to target cell stimulation, despite a rapid acquisition of degranulation ability and MIP-1b
production. Strikingly, rapid reconstitution of cytokine production correlates with a lower relapse incidence
(P ¼ .01) and a better survival rate (P < .0001) at 1 year post-transplant, whereas degranulation capacity was
associated with less relapse (P ¼ .05). Our study demonstrates rapid quantitative reconstitution of the NK cell
compartment despite administration of potent immune suppressive drugs as part of the conditioning
regimen and after transplantation. However, there is a prolonged persistence of functional defects, the
correction of which positively correlates with clinical outcome.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
During the last 3 decades, the use of allogeneic hemato-
poietic stem cell transplantation (HSCT) as a treatment for
hematological malignancies has dramatically increased. It is
well established that allogeneic HSCT exerts immune-
mediated antitumor effects (the so-called graft-versus-leu-
kemia or graft-versus-tumor effect), although the exact
mechanisms that mediate this action remain elusive. Theseedgments on page 438.
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ty for Blood and Marrow Transplantation.mechanisms require effective donor-derived immune
reconstitution in the recipient.
Historically, myeloablative conditioning (MAC) was
commonly used to create space in the recipient marrow and
for its antitumor effect. However, adverse effects and
transplantation-relatedmortality hampered access to elderly
and less ﬁt patients. In attempt to preserve most of the
therapeutic effects of allogeneic HSCT and to overcome pre-
viously mentioned limitations, reduced-intensity (non-
myeloablative) conditioning regimens (RICs) were
introduced and tested with success with respect to
transplantation-related mortality.
Natural killer (NK) cells are antitumor innate lymphoid
cells. Donor-derived NK cells appear rapidly during
Table 1
Patient Characteristics
Donor Origin Total
MRD MUD
N (%) 31 (69) 14 (31) 45
Median age, yr (range) 53 (28-68) 52 (25-69) 53 (25-69)
Diagnosis
Lymphoid 15 (48) 9 (64) 24 (53)
ALL 3 2 5
CLL 2 2 4
NHL 7 2 9
MM 3 3 6
Myeloid 16 (52) 5 (36) 21 (47)
AML 13 4 17
MDS 3 1 4
GVHD
Acute 5 (16) 8 (57) 13 (29)
Chronic 13 (42) 5 (36) 18 (40)
Survival* 20 (65) 11 (78) 31 (69)
Relapse 10 (32) 2 (14) 12 (27)
NRM 2 (6) 1 (7) 3 (7)
CR 21 (68) 11 (78) 32 (71)
CMV reactivation 7 (23) 5 (36) 12 (27)
Median follow-up,
days (range)
420 (232-553) 411 (222-494) 416 (222-553)
ALL indicates acute lymphoid leukemia; NHL, non-Hodgkin lymphoma;
MM, multiple myeloma; AML, acute myeloid leukemia; MDS, myelodys-
plastic syndrome; NRM, nonrelapse mortality; CR, complete remission.
Values are number of incidences with percents in parentheses, unless
otherwise indicated.
*Patients alive at the end of the study.
C. Pical-Izard et al. / Biol Blood Marrow Transplant 21 (2015) 429e439430immune reconstitution after allogeneic HSCT following
myeloablative conditioning [1,2]. NK cells exert their anti-
leukemic activity both by direct killing of tumor cells and
by warning other immune cells via proinﬂammatory cyto-
kines (such as IFN-g and TNF-a) or chemokines (such as
MIP-1b). NK cells express a large array of activating re-
ceptors recognizing stress-induced ligands or adhesion
molecules. In contrast, they also express inhibitory re-
ceptors that recognize classical and nonclassical HLA-I
molecules and are clonally expressed (ie, expression fre-
quencies vary within the pool of NK cells of a given indi-
vidual) [3-5]. Inhibitory NK receptors include the C-type
lectin NKG2A (heterodimerized with CD94) and the killer
cell immunoglobulin-like receptors (KIRs). Expression of
these receptors varies over the lifetime of an NK cell.
Triggering of effector functions is the result of an initial
phase of NK cell education, followed by the encounter with
target cells. Upon interaction with target cells, activation of
NK cells depends on a ﬁnely tuned balance between acti-
vating and inhibitory signals.
Human NK cells are commonly divided into CD56bright
and CD56dim NK cells [1-3,6-9]. NK cells develop from com-
mon lymphoid progenitors into CD56bright NK cells express-
ing high levels of NKG2A. CD56bright NK cells give rise to
CD56dim NK cells, partially losing NKG2A expression and
acquiring KIRs [1,3-5,10,11]. CD56dim NK cell maturation
further continues until terminal differentiation associated
with expression of CD57 and NKG2C [1,12-14].
The antitumor activity of allogeneic NK cells has been
difﬁcult to show in the past years, until the pioneering work
of Ruggeri et al. [15,16] that demonstrated the high potential
of alloreactive HLA-haplomismatched NK cells in HSCT. Un-
fortunately, HSCT with megadoses of immuno-selected
CD34þ obtained from a related haploidentical donor after
administration of a MAC regimen to the recipient causes
signiﬁcant morbidity and is not commonly used outside of
rare experienced centers. Today, HLA-matched HSCT remains
the most common procedure. HLAmatching limits the risk of
graft-versus-host disease (GVHD) triggered by alloreactive T
cells; whether alloreactive NK cells can exert antitumor ef-
fects in this setting remains unclear, because “KIR matching”
is the consequence of HLA matching in siblings. Several
retrospective studies were conducted to understand the role
of NK cells in the graft-versus-leukemia effect of HSCT [4,17-
19]. Unfortunately, it is difﬁcult to draw ﬁrm conclusions
from these studies because of the heterogeneity of cohorts,
conditioning, and cell source (matched unrelated [MUD] or
related [MRD] donors).
Most published studies that describe NK cell reconsti-
tution after HSCT do not include an accurate evaluation of
NK cell phenotype and function. We and others have shown
that NK cells develop quickly in recipients after MRD HSCT
and express KIRs and NKG2A, with similar proﬁles
compared with donors [1,2,20-23]. However, these studies
were based on heterogeneous cohorts of donors/patients or
conditioning regimens. Moreover, most studies were per-
formed in recipients who received MAC rather than RIC
regimen.
We performed a detailed and sequential analysis of the
development and functions of NK cells in a homogeneous
cohort of patients treated with MRD or MUD HSCT after a RIC
regimen. We analyzed the maturation of NK cells as it
conditions effector functions and monitored the capacity of
patients’ NK cells to develop efﬁcient multiparametric
effector functions. Finally, we analyzed the association of allbiological parameters regarding NK reconstitution with
clinical parameters.
METHODS
Patients and Samples
We analyzed peripheral blood mononuclear cells (PBMCs) of 45 pa-
tients who received allogeneic SCT from HLA-matched donors (Table 1).
All patients received the same RIC regimen (ﬂudarabine 30 mg/m2/day,
busulfan 3.2 mg/kg/day) and antithymocyte globulin 5 mg/kg for 2 days.
The source of stem cells was minimally manipulated granulocyte colony-
stimulating factoremobilized PB (no immune selection of CD34þ cells).
Post-transplantation GVHD prophylaxis consisted of cyclosporine A up to
100 days and was tapered afterward in the absence of GVHD. Bulk-
chimerism was routinely studied as part of clinical procedures and was
>80% at day 90 post-HSCT (data not shown).
Before scientiﬁc use of samples and data, patients were appropriately
informed and asked to consent in writing, in compliance with French and
European regulations. This protocol was approved by our institutional re-
view board (no. 12-002). The study was carried out in accordance with the
principles of the Declaration of Helsinki.
Samples were obtained at different times postgraft. Whole PB samples
were processed by Ficoll density centrifugation and were cryopreserved
until use. Healthy control PB from the local blood bank was obtained and
processed similarly to patient samples and used as controls in all experi-
ments. Follow-upwasmeasured from the date of transplantation to the date
of last information for living patients. Median time to relapse was 3 months
(range, 49 to 215 days). Median time to death was 6.3 months (range, 103 to
548 days). Of note, 80% of patients who relapsed died afterward (median
survival postrelapse, 67 days).
Cells
NK cell reactivity was evaluated after interaction with the eryth-
roleukemia cell line K562. K562wasmaintained in RPMI 1640 supplemented
with 10% FCS, 100 U/mL penicillin, and 100 U/mL streptomycin (complete
medium). The follicular lymphoma cell line RL was cultured in complete
medium. Acutemyelogenous leukemia blasts and B-cell chronic lymphocytic
leukemia (B-CLL) cells were obtained from the local biobank as frozen sam-
ples. Only samples containing more than 90% of leukemic cells were used.
Antibodies and Flow Cytometry
The list of antibodies used in the study are presented in Supplementary
Table 1. Data were acquired on an LSR Fortessa (BD Biosciences) and
analyzed with FlowJo 9.6 (FlowJo, LLC, Ashland, OR). Graphics were
Figure 1. Rapid reconstitution of NK cells after HLA-matched HSCT. Kinetics of
NK cell reconstitution after MRD (plain line) or MUD (dashed line) HSCT. NK
cell counts (mean  SEM) were measured at the indicated time points post-
graft and compared with each other and with healthy controls (mean  SEM,
gray shade). NK cell numbers for MUD patients at 4 to 6 months could not be
determined. *P < .05 (comparison between MRD, MUD patients values versus
healthy control subjects).
C. Pical-Izard et al. / Biol Blood Marrow Transplant 21 (2015) 429e439 431generated with Graphpad Prism software or with SPICE software (V5, from
M. Roederer, National Institutes of Health, Bethesda, MD).
NK Cell Functions
Effector functions of NK cells were assessed by ﬂow cytometry. For
target cell stimulation, 1.106 PBMCs were mixedwith K562 (ratio of 10:1) for
4 hours at 37C and 5% CO2 as previously described [10]. Unless otherwise
speciﬁed, PBMCs were kept unstimulated before functional assays. When
indicated, PBMCs from healthy control subjects or patients were primed
overnight with recombinant (r)IL-2 (50 UI/mL) and rIL-15 (5 ng/mL) before
functional assays (see Supplementary Figure 2A). For cytokine production
assays after cytokine stimulation, PBMCs were thawed, counted, and incu-
bated at 2.106 cells/mL for 18 hours in the presence or absence of rIL-12
(5 ng/mL) and rIL-18 (20 ng/mL). Cells were then incubated with or
without target cells with Golgiplug (BD Biosciences) for 4 more hours and
were prepared for ﬂuorescent activated cell sorter analysis.
HLA and KIR Genotyping
High-resolution genotyping of HLA-A, -B, -Cw, -DRB1, and -DQB1 of
recipients and healthy control subjects was performed by PCR-SSP (Olerup
SSP, Bionobis, France). HLA-C alleles were characterized to the level allowing
assignment of HLA-C groups 1 and 2 (HLA-C1 and HLA-C2) on the basis of
the codon determining amino acid at position 80. KIR genotyping of healthy
control subjects and donorswas performed using a PCR-SSP kit (Dynal, Paris,
France) according to the manufacturer’s instructions. In total, 14 KIR genes
were analyzed.
Statistical Analysis
Statistical analyses were performed using Graphpad Prism software.
Comparative analyses between multiple independent groups were per-
formed using Kruskal-Wallis tests and Dunns post-tests. For comparison
between multiple matched samples, a Friedman test with a Dunns post-test
was performed. For comparison between 2 independent groups, a Mann-
Whitney test was performed. Contingency tables were analyzed by
Fisher’s exact tests. Analysis and presentation of distributions (see Figure 4)
was performed using SPICE software. Comparison of distributions was
performed using a Student’s t-test and a partial permutation test as
described [24]. Statistical signiﬁcancewas indicated as *P< .05, **P< .01, and
***P < .001. In all graphs, data represent means  SEM.
Comparison between biological data and clinical outcomes were made
by regression analysis methods, in particular binary logistic for association
with GVHD (both acute and chronic) and Cox regression for associationwith
overall survival (OS) or relapse. To graphically represent the results, Kaplan-
Meier and cumulative incidence curves were built, starting from the time
point “1month after transplant,”which was the time at which the biological
parameter was measured, with the exception of the curves estimating the
outcomes up to 1 year after HSCT, in which the starting day was the day of
transplantation. Cumulative incidence of relapse was calculated using
competing risk analysis, considering death without relapse as competing
event; cumulative incidence of GVHD was calculated considering relapse
and death without GVHD as competing events (from Statistical guidelines
for EBMT, available at https://portal.ebmt.org/sites/clint2/clint/Documents/
StatGuidelines_oct2003.pdf).
Log-rank and Grey tests were used for comparison between groups
whenever applicable. P < .05 was considered as signiﬁcant, and estimates of
hazard ratios were provided together with the respective 95% conﬁdence
intervals. Because of the relatively small number of patients and taking into
account the clinical homogeneity of the cohort (conditioning regimen, HLA
compatibility, etc.), only univariate comparisons were performed. The chi-
square test was used to test for any association between GVHD and cyto-
megalovirus (CMV) reactivation. Clinical data were updated as of July 15,
2014. A consort diagram presents the follow-up of patients studied (see
Supplementary Figure 4).
RESULTS
Comparable NK Cell Reconstitution in MRD and MUD
HSCT
We analyzed the PB of 45 patients after HSCT with HLA-
matched donors with RIC. Analysis of samples from pa-
tients post-conditioning but pretransplant was also
attempted; however, there was insufﬁcient numbers of NK
cells to perform phenotypic or functional analyses. NK cell
numbers in patients were comparable with those of healthy
control subjects 3 months after HSCT (Figure 1). Recipients of
MUD transplants tended to keep lower NK cell counts for alonger period of time than recipients of MRD transplants
(2 to 3 months: 156  56 compared with 265  36, respec-
tively; not signiﬁcant). Frequencies of NK cells were higher in
patients compared with healthy control subjects and
remained high until late time points; no difference was
found between MRD and MUD transplanted patients (data
not shown).
Immature Phenotype of Reconstituting NK Cells
We next analyzed the maturation status of NK cells
developing in MUD and MRD patients. CD3-CD56þ NK cells
were analyzed for the surface density of CD56 and CD16. As
expected, the most immature population was prominent at
early time points (Figure 2A,B). Hence, frequencies of
CD56bright NK cells remained higher in MUD and MRD
transplanted patients compared with healthy control sub-
jects and were only restored at late time points (Figure 2B,
left). Alternatively, CD56dim NK cells frequencies were lower
but restored with time (Figure 2B, right). Maturation of NK
cells is also associated with a loss of expression of the
inhibitory receptor CD94/NKG2A and the acquisition of CD57
[1,3-5,20]. Accordingly, NKG2AþCD56dim NK cell frequencies
were extremely high shortly after HSCT, and these fre-
quencies remained high even at the latest time point, albeit
an evident decrease was observed (Figure 2C, left). Oppo-
sitely, CD57 expression was signiﬁcantly lower than that of
healthy control NK cells at early time points, but frequency
increased with time until reaching the level of controls
(Figure 2C, right).
Finally, KIR expression was analyzed on developing
CD56dim NK cells. Overall, NK cells rapidly expressed all KIRs
tested after HSCT (Figure 3). Interestingly, KIR2DL1/S1 was
expressed at lower levels in HSCT patients. Their frequency
was comparable in MRD and MUD transplanted patients.
Frequencies of KIR2DL1/S1-positive NK cells increased
slowly with time but remained somewhat lower than that of
healthy controls.
Normal Degranulation and Chemokine Production but
Impaired Proinﬂammatory Cytokine Production by
Developing NK Cells
We next assessed the functional properties of developing
NK cells. Based on previouswork, we developed an assay that
assessed the production of MIP-1b, IFN-g, and TNF-a by NK
Figure 2. Reconstituting NK cells display an immature phenotype. (A) PBMCs were stained with anti-CD3, CD56, and CD16 mAbs. Samples were analyzed by ﬂow
cytometry, and representative ﬂuorescent activated cell sorter plots are shown for 1 patient at different times after graft (indicated within each plots). The pro-
portions of CD56bright CD16neg/low, and CD56 dim CD16high indicated in the gates were calculated in the CD3e live cell lymphocyte population. m indicates months;
DCM, dead cell marker. (B) The frequencies of CD56bright (left) and CD56dim NK cells (right) among total NK cells are represented in healthy control subjects (HC, black
boxes) and in patients transplanted with a HLA-MRD (white boxes) and a, HLA-MUD (gray boxes) at different time points after graft. (C) Expression of NKG2A (left)
and CD57 (right) were analyzed on CD56dim NK cells in healthy control subjects (HC, black boxes) and in patients transplanted with a HLA-MRD (white boxes) and a
HLA- MUD (gray boxes) at different time points after graft. Data represent Tukey whisker boxes, with outliers represented as round dots. When indicated, a Kruskal-
Wallis nonparametric test with Dunns post-test was performed to compute the P value for the comparisons. *P < .05, **P < .01, ***P < .001.
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ities by means of CD107a [1,10,12-14,25]. The proﬁle of the
responses displayed by unstimulated NK cells after K562 cell
interaction was analyzed (Figure 4A, Supplementary
Figure 1). At all time points post-HSCT, reconstituting NK
cells degranulated similarly to healthy controls. Production
of MIP-1b after interaction with K562 was similar to that of
healthy controls. In sharp contrast, K562-induced production
of TNF-a and IFN-g was severely impaired in reconstituting
NK cells, and the production of cytokines remained low even
at late time points. When subdividing the cohort in MRD and
MUD transplanted patients, we observed that NK cells from
MUD transplanted patients have a lower proinﬂammatory
cytokine production potential compared with NK cells fromMRD transplanted patients (in which production was lower
than healthy controls) (Figure 4B).
Because the HSCT antitumor effect is expected to be
mediated by the reconstituting immune system, we analyzed
the reactivity of reconstituting NK cells against leukemic
cells known to be resistant to NK killing. NK cells failed to
degranulate against follicular lymphoma cells (RL cell line,
Supplementary Figure 2A). Improving NK cell reactivity with
IL-2 þ IL-15 stimulation before incubation with RL cells
resulted in enhanced degranulation and IFN-g production by
NK cells upon interaction with target cells. Furthermore, we
tested the reactivity of developing NK cells against primary
B-CLL (Supplementary Figure 2B). As expected, B-CLL cells
did not activate NK cells [1,2,26]. Usually, anti-CD20 therapy
Figure 3. Expression of the main KIR by developing NK cells. Expression of KIR2DL1/S1 (left), KIR2DL2/L3/S2 (middle), and KIR3DL1 (right) were analyzed on CD56dim
NK cells in healthy control subjects (HC, black boxes) and in patients transplanted with an HLA-MRD (white boxes) and an HLA-MUD (gray boxes) at different time
points after graft. Data represent Tukey whisker boxes, with outliers represented as round dots. When indicated, a Kruskal-Wallis nonparametric test with Dunns
post-test was performed to compute the P value for the comparisons. *P < .05, **P < .01, ***P < .001.
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rituximab during the co-culture with B-CLL cells resulted in
enhanced degranulation and MIP-1b and cytokine produc-
tion by developing NK cells.
Overall, these data suggest that recovery of cytolytic ac-
tivity and chemokine production is faster than recovery of
proinﬂammatory cytokines. Antitumor activity of NK cells
may be limited at steady state but could be enhanced by
therapeutic reagents.
Normal Cytokine Production by Reconstituting NK Cells
upon Exogenous Cytokine Stimulation
As a consequence of an immature phenotype of NK cells
after HSCT, we hypothesized that these cells would respond
efﬁciently to exogenous cytokine stimulation [3-5,20,22].
We tested the capacity of patients’ NK cells from theFigure 4. Dissociation between NK cells degranulation and cytokine production. (A) N
were co-cultured with K562 cells for 4 hours and stained for surface CD107a, or intr
quency) of the indicated responses measured. (B) Comparison of CD107a, MIP-1b, IF
grafted with cells from MRDs or MUDs. Data represent Tukey whisker boxes, with o
metric test with Dunns post-test was performed to compute the P value for the comearliest time points to produce TNF-a and IFN-g in response
to IL-12/IL-18 stimulation. Reconstituted NK cells were
capable of producing both cytokines similarly to healthy
control subjects (Figure 5A). Interestingly, pretreatment of
NK cells by IL-12/IL-18 increased the level of degranulation
against K562 but also the level of TNF-a produced upon
target cell interaction (Figure 5B). Unsurprisingly,
pretreatment of NK cells with IL-12/IL-18 had little effect
on target cell-induced IFN-g production (Figure 6B, right)
[1-3,6-9,20]. Hence, IL-12/IL-18 is the optimal stimulation
to induce IFN-g production by NK cells [1,3-5,10,11,27], and
the addition of a target cell stimulation may not enhance
further such a high response.
Next, we analyzed the multiparametric response of NK
cells after IL-12/IL-18 þ K562 stimulation (Figure 5C). The
magnitude of the overall response (frequency of eitherK cells from healthy control subjects (HC) and patients at different time points
acellular MIP-1b, IFN-g, or TNF-a. Data represent the relative proportion (fre-
N-g, and TNF-a production after interaction with K562 cells between patients
utliers represented as round dots. When indicated, a Kruskal-Wallis nonpara-
parisons. *P < .05, **P < .01, ***P < .001.
Figure 5. Normal cytokine production by reconstituting NK cells upon exogenous cytokine stimulation. (A) Production of TNF-a and IFN-g by NK cells from healthy
control subjects (HC, n ¼ 3) and patients 1 month after HSCT (n ¼ 3) in response to IL-12/IL-18 stimulation. (B) PBMCs from healthy control subjects (HC, black bars)
and recipients 1 month after HSCT (gray bars) were incubated overnight with media alone or with IL-12/IL-18 and then co-cultured with K562 cells or with medium
alone for 4 hours. After incubation, CD107a expression and TNF-a and IFN-g production were measured on CD56þCD3e NK cells. Bars represent the mean  SEM. (C)
NK cells were stimulated with IL-12þIL-18 and co-cultured with K562 for 4 hours. CD56dim NK cells were gated and a Boolean gating strategy was used for analysis.
We analyzed the proportion of the different types of responses displayed by responding NK cells. Pie charts represent the frequency of cells positive for the given
number of measured responses (CD107a, TNF-a, and IFN-g). Cells are plotted against the number of responses they display. Arcs depict the relative frequency of cells
speciﬁcally positive for CD107a, TNF-a, and IFN-g staining, as indicated. Values represent the mean of 3 different patients.
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healthy control subjects and HSCT patients at 1 and 2 to
3 months post-HSCT (73.5%  16% versus 88.2%  6.7% and
81.2%  4.3%, respectively; not shown). However, when only
looking at responding cells, we observed that HSCT patients
displayed less multifunctional responses, mostly IFN-g
triggered by IL-12/IL-18, compared with healthy control
subjects (Figure 5B,C). These data suggest that although
exogenous cytokine stimulation allowed HSCT NK cells to
produce IFN-g similarly to healthy controls, interaction with
target cells may not result in optimal response from recon-
stituting NK cells.
Impact of CMV on NK Cells after HSCT
Interestingly, we observed a lower degranulation by NK
cells from patients experiencing CMV reactivation, compared
with NK cells from patients without (median, 9.56% CD107aþ
NK cells versus 16.26%, respectively, P ¼ .0227). In parallel,
TNF-a production was lower in patients who reactivated
CMV compared with patients without CMV reactivation
(median, 2.1% versus 5.1%, respectively, P ¼ .0085). Further-
more, we observed an expansion of NKG2AeNKG2CþCD57þ
NK cells with frequencies sometimes higher than in healthy
controls, especially at the latest time points (Figure 6A,P ¼ .01). Studies have highlighted the expansion of
NKG2AeNKG2CþCD57þ NK cells after HSCT [3,6-9,27]. This
population has since been associated with memory-like
properties that can be induced either by viral infection, like
CMV, and/or cytokine stimulation [1,3,6,8-11,13,20]. Here,
NKG2AeNKG2CþCD57þ NK cells displayed a largely skewed
proﬁle with a higher frequency of KIR2DL2/L3/S2 expression
either alone or in combination with other KIRs (Figure 6B).
The frequency of this population was higher in patients
receiving a graft from CMV-seropositive donors (P ¼ .0298)
or in patients whowere seropositive at the time of transplant
(Figure 6C, P ¼ .0001). As a control, we did not observe any
change in KIR proﬁles at the total NK cell population in pa-
tients experiencing CMV reactivation (Supplementary
Figure 3). In addition, CMV reactivation after HSCT resulted
in a signiﬁcant increase in the frequency of the
NKG2AeNKG2CþCD57þ cell population (Figure 6D).
A Better Phenotypic or Functional Reconstitution
Correlates with a Better Clinical Outcome
We hypothesized that, similarly to what has been shown
in previous studies performed in the context of MAC HSCT, a
better NK cell reconstitution would be associated with a
better clinical outcome. As expected, donor type (MRD or
Figure 6. Expansion of NKG2AeNKG2CþCD57þ CD56dim NK cells after HSCT. (A) NKG2A negative CD56dim NK cells from healthy control subjects (HC, white bars) and
patients at different time points after HSCT were gated into CD57þNKG2Cþ, CD57þNKG2Ce, CD57eNKG2Cþ, or CD57eNKG2Cepopulations. (B) The total CD56dim NK
cells (white bars) and the NKG2AeCD57þNKG2Cþ population (black bars) were classiﬁed according to the number and the type of KIRs markers expressed on their
surface. (C) Frequencies of NKG2AeCD57þNKG2Cþ CD56dim NK cells are depicted according to the CMV activation status of the patients (left) or donors (right). (D)
Frequencies of NKG2AeCD57þNKG2Cþ CD56dim NK cells in the presence or absence of CMV reactivation after HSCT. Bars represent the means  SEM. When indicated,
a Kruskal-Wallis nonparametric test with Dunns post-test was performed to compute the P value for the comparisons between the different subsets with the
corresponding subset in HC. *P < .05, **P < .01, ***P < .001.
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tivation was associated with GVHD, donor type, and patient
or donor CMV status (P < .05, data not shown). Next, uni-
variate comparisons were performed between NK cell
counts, maturation marker expression (CD56, NKG2A, CD57)
and KIR expression, functional parameters at 1 month after
HSCT, and clinical outcomes such as OS and relapse. Samples
of 26 patients who were event-free at 1 month post-graft
were included in the analysis (for patient details see
Supplementary Figure 4). Importantly, a rapid and better
reconstitution of TNF-a production signiﬁcantly correlated
with OS (P < .0001, Figure 7A, left) because of an inferior
incidence of relapse (P ¼ .01, Figure 7B, left). Additionally, we
observed that at the 1-month time point, TNF-a production
was higher in NK cells from patients that survived at 1 year
post-HSCT (1.7%  1% versus 7%  2%, time point ¼ 1 month,
P ¼ .0012, Figure 7A, right) as well as in patients who did not
relapse after 1 year post-graft (P ¼ .01, Figure 7B, right). Also
interesting was that although not signiﬁcant, NK cells fromsurviving patients (at 12 months) degranulated better when
compared with NK cells from patients who later died
(19%  9% versus 10.5%  4% respectively, P ¼ .0593, data not
shown).
Nonrelapse mortality is usually considered as a con-
founding factor but could not be studied here because of the
rarity of events (n ¼ 2, Supplementary Figure 4). Moreover,
low degranulation correlated with a higher incidence of
1-year relapse (P ¼ .09, Figure 7C, left). Indeed, the levels of
CD107a expression by NK cells at 1 month were lower in
patients who later relapsed compared with nonrelapsing
patients (P ¼ .012, Figure 7C, right). In addition, when the
CD107a parameter was considered as a continuous variable,
we observed that increased CD107a expression conferred
protection from relapse in the ﬁrst year after HSCT (hazard
ratio, .73; 95% conﬁdence interval, .53 to .99; P ¼ .05, not
shown). Although not statistically signiﬁcant, higher
CD56dim NK cell frequencies correlated with better OS
(P ¼ .09, n ¼ 23, Figure 7D), and increased IFN-g production
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versus 37% with IFN-gþ cells > 2% versus  2%, respectively;
P ¼ .21; n ¼ 13, not shown). Overall, these analyses indicate
that patients with better reconstituted NK cells may have a
better outcome.DISCUSSION
HLA-matched HSCT with RIC is now a commonly used
therapeutic option for patients with advanced or high-risk
hematological malignancies. In this setting the develop-
ment, acquisition of effector functions, and antitumoral ac-
tivity of NK cells remains elusive. Here we compared the
development of NK cells and the acquisition of their effector
functions in MRD and MUD transplanted patients with RIC.
Our data showed that recovery of numbers and percentages
of NK cells is rapid in both MRD and MUD transplanted pa-
tients. Developing NK cells maintained an immature
phenotype characterized by a high frequencies of CD56bright
NK cells and NKG2AþCD57e CD56dim NK cells. With respect
to NK cell functions, degranulation and MIP-1b secretion
abilities were similar to controls; however, target cellein-
duced IFN-g and TNF-a production was impaired. Finally, we
observed statistical correlations between reconstitution of
NK cell phenotype and functions with a better clinical evo-
lution of patients.
Interestingly, the immature phenotype observed for most
patients was maintained for at least 6 months, which is
puzzling in that this probably represents several generations
of NK cells developing in the recipients. The prominent
persistence of CD56bright and immature NKG2AþCD56dim NK
cells could be a consequence of GVHD prophylaxis with
cyclosporine A, which is known to reduce CD56dim NK cell
proliferation [15,16,25]. With respect to KIR expression, we
observed that developing NK cells readily express KIRs at the
end of the ﬁrst month, irrespective of the donor type. Hence,
frequencies of KIR expression were comparable with healthy
control subjects and remained stable over time, albeit with a
low frequency KIR2DL1/S1 expression compared with
healthy control subjects. This ﬁnding is in line with previous
studies [4,17-19,23], and may be due to the expression of the
alternate HLA-C1/C2 receptor KIRD2LD2, which was well
represented in our cohort (data not shown; M. Urhberg,
personal communication) [1,2,12,20-23,29]. In addition, we
observed an expansion of NKG2AeNKG2CþCD57þ CD56dim
NK cells in our patients in both MRD and MUD groups. As
documented before, the expansion of this “memory-like” NK
cell is higher in patients who experienced CMV reaction and
is associated with a prominent expression of KIR2DS2/L2/3
[1,3-5,10,13,14,15,16,20,24,28]. It is possible that cytokines in
the milieu, shortly after engraftment, may induce the
expansion of these memory-like NK cells [3,6-9,17,27,30,31].
However, the association between CMV reactivation and a
lower degranulation or TNF-a production by total NK cells
prompts further analysis of the functional properties of these
memory-like NK cells.Figure 7. NK cell reconstitution correlates with clinical outcome. (A) OS according t
patients with <3.5% of TNF-aeproducing cells (n ¼ 6) was 0%, versus 75% of those wit
cells producing TNF-a at 1 month after HSCT. Relapse of patients with <3.5% of TNF
P ¼ .01. (C) Relapse incidence according to degranulation measured as the percentage o
75%, versus 22% of those with >10% (n ¼ 10); P ¼ .09. (D) OS according to percentage o
43%, versus 81% of those with >30% (n ¼ 16); P ¼ .09). Patients at risk are indicated
lationships, displayed as Tukey whisker boxes, between the biological parameters ob
patient survival (alive at 12 months post-HSCT) or relapse (at 12 months). Patient nuThe dichotomy between degranulation/chemokine pro-
duction and IFN-g/TNF-a production, as previously observed,
is also in line with the delayed maturation of NK cells after
HSCT [18]. Hence, it is known that immature CD56bright and
NKG2AþCD56dim NK cells have a higher propensity to pro-
duce cytokines upon exogenous cytokine stimulation
compared with more mature NK cells [1,7,10,12-14,20,25,27].
Alternatively, cyclosporine A is also known to reduce target
celleinduced IFN-g production and enhance cytokine-
induced IFN-g production by human NK cells [32]. Howev-
er, the latter conclusion remains controversial because
another study showed that cyclosporine A did not alter
cytokine production by NK cells [33]. In contrast, the authors
found that cytolytic activity is impaired by in vitro treatment
with cyclosporine A, which is the opposite of our ﬁnding.
These studies have been performed on ex vivo NK cells
stimulated with cyclosporine A in the presence or absence of
IL-2 or IL-15, which by far reﬂects the situation in patients
where the treatment with cyclosporine A lasts several weeks.
Therefore, it is difﬁcult to draw any conclusion on the impact
of cyclosporine A in the development of NK cells after HSCT
from our study.
With respect to cytotoxicity, patients’ NK cells rapidly
behaved similarly to healthy control subjects’NK cells, in that
they would require additional “help” to conduct signiﬁcant
antitumor activity, especially against NK-resistant leukemic
cells. Our preliminary results show that the use of rituximab
during the co-culture of NK cells with leukemic B cells from
B-CLL patients restored the recognition of B-CLL cells by
patients NK cells. Similarly, priming NK cells from a patient
suffering from a follicular lymphoma (FL) with IL-2þIL-15
restored their reactivity against a FL cell line. These data
suggest that therapies complementary to HSCT, such as
blocking antibodies, cytokines, or immunomodulatory drugs,
may be useful to treat refractory patients or residual disease
[21,23,34-36].
Finally, our data showed that a better reconstitution of NK
cells, in particular the functional parameters TNF-a, IFN-g,
and degranulation, correlated with less adverse events such
as death and relapse at 12 months, CMV reactivation, and
GVHD (although correlation with GVHD did not reach sig-
niﬁcance at 1 month post-graft; not shown). These data
require conﬁrmation in a larger cohort, especially to rule out
confounding parameters such as nonrelapse mortality, dis-
ease relapse index (DRI), or Sorror index. Nevertheless, these
analyses strongly suggest that NK cells may participate in the
antitumor effect of HSCT. Hence, our data strengthen other
studies performed in different settings of HSCT (such as MAC
or T celledepleted HSCT) [37]. One could question whether
the better clinical outcome is actually dependent, at least
partially, on the quality of NK cell development or whether a
better clinical evolution of patients promotes a good NK cell
reconstitution. Moreover, as our analysis concerns only NK
cells, we cannot exclude the participation of other immune
cells to the positive effect of NK cells. For instance, little is
known about the reconstitution of monocytes after HSCT oro percentage of NK cells producing TNF-a at 1 month after HSCT. Survival of
h >3.5% (n ¼ 7); P < .0001. (B) Relapse incidence according to percentage of NK
-aeproducing cells (n ¼ 6) was 83%, versus 31% of those with >3.5% (n ¼ 7);
f CD107aþ NK cells. Relapse of patients with <10% of CD107aþ cells (n ¼ 4) was
f CD56dim NK cells. Survival of patients with <30% of CD56dim cells (n ¼ 7) was
below each graph (left panels). Right panels correspond to the statistical re-
tained at 1 month postgraft and clinical outcome at 1 year with the focus of
mbers are indicated under the graphs.
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are a major source of IL-15 necessary for NK cell develop-
ment. Although our data suggest that the early recovery of
NK cell functions positively impacts on clinical outcome, it
remains unclear whether in patients with poor evolution NK
cell functions are somehow suppressed. Most certainly, both
leukemia relapse and the presence of inﬂammation during
GVHD will alter immune cell functions as suggested or
shown by many studies. An argument in favor of a role of NK
cells is that the 1-month time point corresponds to a period
free of adverse events in our cohort (including relapse and
acute GVHD). Nevertheless, these data highlight the need for
further studies to deﬁne the role of NK cells in HSCT and
better exploit these cells in therapy post-allograft.
To conclude, we characterized the development and
acquisition of functions by NK cells in HLA-matched HSCT
after RIC. An homogeneous cohort allowed us to determine
that NK cells develop almost similarly from unrelated or
sibling donors. Developing NK cells rapidly acquire cytolytic
and chemokine production capabilities. In contrast, cytokine
production remained defective but could be enhanced by
exogenous cytokine stimulation. Overall, in this HSCT setting,
the quality of NK cell recovery, with respect to maturation
and functions, correlated with lower incidence of adverse
clinical outcome, such as survival, relapse, GVHD, and CMV
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